Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Özge Erol Fenercioğlu"'
Publikováno v:
Molecular Imaging and Radionuclide Therapy. 32:57-61
Publikováno v:
Clinical Nuclear Medicine. 48:e37-e39
We present 2 patients mimicking malignancy with intense gastric 68 Ga-FAPI-04 uptake on PET/CT. Both patients showed low to moderate 18 F-FDG uptake. Histopathology revealed chronic active gastritis. Chronic gastritis may resemble gastric malignancie
Publikováno v:
Molecular imaging and radionuclide therapy. 31(3)
A 76-year-old man with metastatic prostate cancer was referred toMetastatik prostat kanseri tanılı 76 yaşında erkek hasta yeniden evreleme amacıyla
Publikováno v:
Clinical nuclear medicine.
A 57-year-old man with familial adenomatous polyposis (FAP) and newly diagnosed colonic adenocarcinoma was referred to 18F-FDG PET/CT for staging and 68Ga-FAPI-04 PET/CT for ongoing trial. 18F-FDG PET/CT showed equal intense 18F-FDG uptake in the tum
Publikováno v:
Molecular Imaging and Radionuclide Therapy. 31:157-159
Publikováno v:
Molecular Imaging and Radionuclide Therapy. 31:160-162
Publikováno v:
Clinical Nuclear Medicine. 47:e637-e639
Prostate cancer is the most common cancer in men. 68 Ga-PSMA PET/CT is frequently used in staging and restaging prostate cancer; it is important to keep in mind the causes of false-positives when evaluating imaging. We present findings of 68 Ga-PSMA
Publikováno v:
Clinical nuclear medicine. 47(12)
The 68 Ga-PSMA PET/CT imaging modality is used to evaluate biochemical recurrence, response to treatment, and staging in prostate cancer. Prostate-specific membrane antigen (PSMA) receptor activation can be seen in benign and malignant diseases as we
Publikováno v:
Clinical nuclear medicine. 47(9)
Herein, we present the results of 18F-FDG PET/CT and 68Ga-FAPI-4 PET/CT of a patient with metastatic Kaposi sarcoma. A 47-year-old man with suspected gastric cancer was referred to 18F-FDG PET/CT for diagnosis and staging. PET/CT detected increased 1
Publikováno v:
Clinical Nuclear Medicine. 48:e46-e47
Most patients treated with epidermal growth factor receptor inhibitors develop cutaneous advance effects. The extent and severity of treatment-related skin rashes are associated with good treatment response and prognosis. Herein, we presented increas